Research Paper Volume 15, Issue 1 pp 119—133
Profiling of a novel circadian clock-related prognostic signature and its role in immune function and response to molecular targeted therapy in pancreatic cancer
Figure 2. Evaluation of the performance of the circadian clock-related signature. (A–D) Area under the curve (AUC) for predicting 5-year overall survival were 0.727, 0.732, 0.700, and 0.658 in the training set, the validation set, and the two test sets, respectively. (E–H) KM analysis revealed that the low-risk population had desirable prognostic outcomes compared with the high-risk population in the training set, the validation set and the two external test sets. (I–L) PCA analysis demonstrated that the low-hazard cohort were clearly separated from the high-hazard cohort in Dimension 1.